Search

Your search keyword '"Humalog (Medication) -- Health aspects"' showing total 6 results
Start Over Descriptor "Humalog (Medication) -- Health aspects"
6 results on '"Humalog (Medication) -- Health aspects"'

1. 3 DERMATOLOGICAL DISORDERS

Subjects
Merck & Company Inc., Pfizer Inc., AstraZeneca PLC, Novo Nordisk A/S, Humalog (Medication) -- Health aspects, Glucophage (Medication) -- Health aspects, Diagnosis, Care and treatment, Health aspects, Tetracyclines -- Health aspects, Acne -- Diagnosis -- Care and treatment, Pyrimethamine -- Health aspects, Drospirenone -- Health aspects, Oral contraceptives -- Health aspects, Pharmaceutical industry -- Health aspects, Diarrhea -- Diagnosis -- Care and treatment, Antibacterial agents -- Health aspects, Colitis -- Diagnosis -- Care and treatment, Tetracycline -- Health aspects
Abstract

3A Acne PRESCRIBING NOTES ANTIBIOTICS: Interactions: Systemic antibiotics may reduce efficacy of oral contraceptives. Bactericidal drugs are primarily active against actively dividing cells. Therefore, bacteriostatic antibiotics (eg, tetracyclines) may interfere [...]

Published
2020

2. Metabolic

Author

Celia, Frank

Subjects
Sanofi S.A., NovoLog FlexPen (Drug-delivery device) -- Health aspects, Contrave (Medication) -- Health aspects, NovoLog (Medication) -- Health aspects, Januvia (Medication) -- Health aspects, Humalog KwikPen (Drug-delivery device) -- Health aspects, Lantus Solostar (Medication) -- Health aspects, Levemir FlexPen (Drug-delivery device) -- Health aspects, Humalog (Medication) -- Health aspects, Victoza (Medication) -- Health aspects, Lantus (Medication) -- Health aspects, Saxenda (Medication) -- Health aspects, Janumet (Medication) -- Health aspects, Health aspects, Blood glucose -- Health aspects, Pharmaceutical industry -- Health aspects, Weight loss -- Health aspects, Blood sugar -- Health aspects
Abstract

Is this finally the year that anti-obesity drugs make the leap from niche curio to mainstream therapy? Frank Celia reports on the changing practitioner mind-set that could shift odds in [...]

Published
2015

3. Effectiveness of postprandial Humalog in toddlers with diabetes

Author

Rutledge, K. Suchari, Chase, H. Peter, Klingensmith, Georgeanna J., Walravens, Philip A., Slover, Robert H., and Garg, Satish K.

Subjects
Humalog (Medication) -- Health aspects, Care and treatment, Health aspects, Juvenile diabetes -- Care and treatment, Insulin -- Health aspects, Diabetes in children -- Care and treatment
Abstract

ABBREVIATION. YSI, Yellow Springs instrument. Insulin-dependent (type 1) diabetes mellitus is an autoimmune disease that most commonly has its onset in children and young adults. However, preschool children can also [...]

Published
1997

4. ean Medicine Agency new product details:Pharmacovigilance Risk Assessment Committee (PRAC)Pharmacovigilance Risk Assessment Committee (PRAC)

Subjects
Samsung Bioepis Company Ltd., Bristol-Myers Squibb Co., Boehringer Ingelheim GmbH, Bayer HealthCare Pharmaceuticals, Exelon Corp., Merck Sharp & Dohme Ltd., AstraZeneca PLC, Novo Nordisk A/S, UCB Pharma S.A., Pfizer Ltd., Electric utilities -- Health aspects, Risk assessment -- Health aspects, Pharmaceutical industry -- Health aspects, Business, international, European Union, European Union. European Commission, Prolia (Medication) -- Health aspects, Zinbryta (Medication) -- Health aspects, Exjade (Medication) -- Health aspects, Micardis (Medication) -- Health aspects, Faslodex (Medication) -- Health aspects, Mosquirix (Vaccine) -- Health aspects, Humalog (Medication) -- Health aspects
Abstract

London: European Medicine Agency has issued the following new product details: Minutes of the meeting on 6-9 June 2017 Chair: June Raine - Vice-Chair: Almath Spooner Health and safety information [...]

Published
2017

5. My personal travel tips

Author

Womack, James

Subjects
Humalog (Medication) -- Health aspects, Lantus (Medication) -- Health aspects, Drug therapy, Travel, Health aspects, Type 1 diabetes -- Drug therapy, Diabetics -- Travel -- Health aspects -- Drug therapy
Abstract

Your article 'Have Insulin, Will Travel' (August, page 50) was loaded with good travel tips. I joined the American Diabetes Association shortly after being diagnosed with type 1 in November [...]

Published
2005

6. Canada OKs Vaqta and Humalog

Subjects
Merck Frosst Canada Ltd. -- Product information, Eli Lilly and Co. -- Product information -- 00305219, Vaccines industry -- Product information, Hepatitis A -- Prevention, Pharmaceutical industry -- Product information, Insulin -- Health aspects, Diabetes -- Drug therapy, Business, Pharmaceuticals and cosmetics industries, VAQTA (Vaccine) -- Health aspects, Humalog (Medication) -- Health aspects
Published
1996

Catalog

Books, media, physical & digital resources
See catalog results